We appreciate Dr Suhler et al1 for studying infliximab prospectively for the treatment of refractory uveitis and for the scientific manner in which they evaluated the treatment. We did want to make several points regarding their treatment protocol that may have influenced their associated adverse events. These events are unexpected given that multiple large randomized studies of the anti–tumor necrosis factor (anti-TNF) agents have been conducted with excellent safety profiles and given the successful and extensive use in systemic inflammatory diseases.
Rudometkin N, Mandava N, Deane K, Olson JL. Infliximab in Uveitis Treatment. Arch Ophthalmol. 2006;124(8):1211. doi:10.1001/archopht.124.8.1211-a